Holen Sie sich die Stockscreener-App
0.0067
48.06%
-0.0062
Nls Pharmaceutics Ag Aktie (NLSPW) Neueste Nachrichten
NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN
NLS Pharmaceutics secures $2M for Kadimastem merger - Investing.com
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - StreetInsider.com
NLSP stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa
NLSP stock touches 52-week low at $1.47 amid market challenges - Investing.com India
NLS Pharmaceutics Ltd. (NASDAQ:NLSPW) Short Interest Down 31.6% in February - Defense World
NLS Pharmaceutics announces merger with Kadimastem - Investing.com India
NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com UK
NLS Pharmaceutics CEO Issues Letter to Shareholders - Yahoo Finance
Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - Marketscreener.com
NLSP stock touches 52-week low at $1.71 amid steep annual decline By Investing.com - Investing.com South Africa
NLSP stock touches 52-week low at $1.71 amid steep annual decline - Investing.com India
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq - accessnewswire.com
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement - ACCESS Newswire
AEX-2 increases total wake duration in mouse model - BioWorld Online
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment - ACCESS Newswire
NLS Pharmaceutics reports progress in narcolepsy treatment By Investing.com - Investing.com South Africa
NLS Pharmaceutics reports progress in narcolepsy treatment - Investing.com
Pre-IND meeting guides path forward for ITOL-102 for type 1 diabetes - BioWorld Online
NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - Yahoo Finance
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder - ACCESS Newswire
NLS Pharmaceutics And Kadimastem Unveil Multi-Target Diabetes Approach - Nasdaq
Is NLSP’s price to cash per share ratio a concern for investors? - US Post News
NLS Pharmaceutics (NLSP) Shares Surge As Market Reacts To Potential Merger - Stocks Telegraph
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies - Marketscreener.com
Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews
Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews
NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference - ACCESS Newswire
Dow Edges Lower; Exxon Mobil Earnings Top Views - Benzinga
NLS Pharmaceutics Says Kadimastem Shareholders Approve Merger With NLS; Shares Rise - Marketscreener.com
Nasdaq Jumps Over 150 Points; Apple Posts Upbeat Earnings - Benzinga India
NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice - ACCESS Newswire
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics -January 31, 2025 at 07:31 am EST - Marketscreener.com
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Marketscreener.com
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Benzinga
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions - ACCESS Newswire
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - ACCESS Newswire
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance - ACCESS Newswire
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing - ACCESS Newswire
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform - ACCESS Newswire
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence - ACCESS Newswire
NLS Pharmaceutics Announces Company Update on Strategic Partnerships - ACCESS Newswire
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - ACCESS Newswire
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering - ACCESS Newswire
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - ACCESS Newswire
NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge - ACCESS Newswire
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS - Marketscreener.com
SEC Form 425 filed by NLS Pharmaceutics Ltd. - Quantisnow
Pre-market Movers: HSDT, PBM, MTEM, APTO... - RTTNews
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
2.65%
0.06%
Kapitalisierung:
|
Volumen (24h):